Key facts
- It has raised $87.4M; the latest was Grant ($1.9M) in Jan 2025.
- Notable investors include European Commission, Entrée Capital, b2venture, Bundesministerium für Wirtschaft und Klimaschutz, Lauder Partners — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for NVision Imaging Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for NVision Imaging Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NVision Imaging Technologies
Developer of medical imaging and quantum-enhanced diagnostic systems designed for early assessment of treatment response at the metabolic level. The company integrates hyperpolarization hardware, workflow-compatible preparation of endogenous metabolic agents, rapid signal amplification for use with existing MRI scanners, and software-guided imaging protocols, enabling oncology and broader clinical research and care markets to obtain high-throughput, room-temperature, small-footprint metabolic imaging with cellular-level insight for earlier, more precise evaluation of disease activity and therapy effectiveness.
- Sector
- Healthcare
- HQ
- Ulm, Germany
- Founded
- 2015
- Employees
- 124
- Website
- nvision-imaging.com/
- Ownership
- Privately Held (backing)
NVision Imaging Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NVision Imaging Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NVision Imaging Technologies in its N-PORT filings yet. We sweep new filings monthly.